Skip to main content
Clinical Trials/NCT00156143
NCT00156143CompletedPhase 3

GH Therapy in Partial GHD Adolescents : Evaluation of Efficacy Based on Body Composition and Comparison of 2 Different Doses of Genotonorm®. Open-Label, Randomised, Comparative, Controlled, Parallel-Group, Multi-Center Phase IIIB Clinical Trial.

Pfizer0 sites90 target enrollmentStarted: April 2002Last updated:
Conditions

Trial Snapshot

Phase
Phase 3
Status
Completed
Sponsor
Pfizer
Enrollment
90
Primary Endpoint
Change from baseline of the % of fat mass assessed by DEXA after 1 year of treatment.

Study Overview

Brief Summary

To evaluate in boys and girls the improvement in body composition under GH treatment in adolescents with CO-GHD who remain partially GHD after GH discontinuation.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
15 Years to 20 Years (Child, Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Males or females : Chronological age > or = 15 years and < or = 20 years for females
  • Chronological age > or = 17 years and < or = 20 years for males
  • GHD of childhood onset treated for at least 2 years
  • Last GH injection at least 12 months before baseline visit

Exclusion Criteria

  • Turner's syndrome
  • Chronic hepatic impairment as shown by GGT and / or ASAT and / or ALAT > 2 X ULN

Outcomes

Primary Outcomes

Change from baseline of the % of fat mass assessed by DEXA after 1 year of treatment.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Pfizer
Sponsor Class
Industry

Similar Trials